GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » EBIT

Cibus (CBUS) EBIT : $-331.99 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cibus EBIT?

Cibus's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-18.63 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-331.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cibus's annualized ROC % for the quarter that ended in Mar. 2024 was -14.17%. Cibus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -205.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cibus's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -124.82%.


Cibus EBIT Historical Data

The historical data trend for Cibus's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus EBIT Chart

Cibus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only -38.12 -43.40 -27.77 -16.80 -318.75

Cibus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.37 -17.89 -26.39 -269.07 -18.63

Competitive Comparison of Cibus's EBIT

For the Biotechnology subindustry, Cibus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cibus's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cibus's EV-to-EBIT falls into.



Cibus EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-331.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus  (NAS:CBUS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cibus's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-73.812 * ( 1 - -0.05% )/( (522.64 + 519.563)/ 2 )
=-73.848906/521.1015
=-14.17 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cibus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-74.516/( ( (37.46 + max(-11.855, 0)) + (35.115 + max(-12.849, 0)) )/ 2 )
=-74.516/( ( 37.46 + 35.115 )/ 2 )
=-74.516/36.2875
=-205.35 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.53 + 0 + 1.991) - (7.874 + 1.21 + 5.292)
=-11.855

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.65 + 0 + 1.56) - (8.476 + 1.46 + 5.123)
=-12.849

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cibus's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-331.986/265.980
=-124.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus EBIT Related Terms

Thank you for viewing the detailed overview of Cibus's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cibus (CBUS) Business Description

Traded in Other Exchanges
N/A
Address
6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.
Executives
Rory B Riggs director, officer: Chief Executive Officer 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr. director 1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn 10 percent owner C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante director SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn director VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann director 21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker director 13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King officer: Chief Financial Officer 750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William officer: See Remarks 13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham director, officer: See Remarks 6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill director C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr director, officer: President and CEO 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak officer: Chief Financial Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter officer: Chief Business Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas officer: Chief Science Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113